NO303734B1 - Triazolyltiometyltiocefalosporin-hydroklorid, dets krystallinske hydrat samt farmasaytisk preparat inneholdende dette - Google Patents

Triazolyltiometyltiocefalosporin-hydroklorid, dets krystallinske hydrat samt farmasaytisk preparat inneholdende dette

Info

Publication number
NO303734B1
NO303734B1 NO932745A NO932745A NO303734B1 NO 303734 B1 NO303734 B1 NO 303734B1 NO 932745 A NO932745 A NO 932745A NO 932745 A NO932745 A NO 932745A NO 303734 B1 NO303734 B1 NO 303734B1
Authority
NO
Norway
Prior art keywords
crystalline hydrate
hydrochloride
triazolylthiomethylthiocephalosporin
pharmaceutical composition
composition containing
Prior art date
Application number
NO932745A
Other languages
English (en)
Norwegian (no)
Other versions
NO932745L (no
NO932745D0 (no
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO932745D0 publication Critical patent/NO932745D0/no
Publication of NO932745L publication Critical patent/NO932745L/no
Publication of NO303734B1 publication Critical patent/NO303734B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO932745A 1992-07-31 1993-07-30 Triazolyltiometyltiocefalosporin-hydroklorid, dets krystallinske hydrat samt farmasaytisk preparat inneholdende dette NO303734B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (3)

Publication Number Publication Date
NO932745D0 NO932745D0 (no) 1993-07-30
NO932745L NO932745L (no) 1994-02-01
NO303734B1 true NO303734B1 (no) 1998-08-24

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932745A NO303734B1 (no) 1992-07-31 1993-07-30 Triazolyltiometyltiocefalosporin-hydroklorid, dets krystallinske hydrat samt farmasaytisk preparat inneholdende dette

Country Status (23)

Country Link
US (1) US5407929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0581552B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100245938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1037683C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE165360T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU657866B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9303235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2101502A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69318077T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2115725T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI933391A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3026699T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU219637B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL106516A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9304611A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO303734B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ248285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL172835B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2118959C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA37181C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA935529B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2298769E (pt) * 2001-02-24 2013-11-29 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como produto farmacêutico
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
PL376557A1 (pl) 2003-02-12 2006-01-09 Ciba Specialty Chemicals Holding Inc. Postacie krystaliczne pitawastatyny wapnia
PT1606293E (pt) 2003-03-27 2009-10-14 Basilea Pharmaceutica Ag Cefalosporina sob forma cristalina
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
CN1037683C (zh) 1998-03-11
CA2101502A1 (en) 1994-02-01
AU657866B2 (en) 1995-03-23
AU4422793A (en) 1994-02-03
FI933391L (fi) 1994-02-01
NO932745L (no) 1994-02-01
ZA935529B (en) 1994-02-24
TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-06-11
PL299870A1 (en) 1994-02-07
EP0581552A3 (en) 1994-06-01
UA37181C2 (uk) 2001-05-15
PL172835B1 (pl) 1997-12-31
IL106516A (en) 1998-06-15
US5407929A (en) 1995-04-18
ATE165360T1 (de) 1998-05-15
FI933391A0 (fi) 1993-07-29
PH30109A (en) 1996-12-27
KR100245938B1 (ko) 2000-04-01
GR3026699T3 (en) 1998-07-31
ES2115725T3 (es) 1998-07-01
CN1089948A (zh) 1994-07-27
EP0581552B1 (en) 1998-04-22
KR940005636A (ko) 1994-03-22
HU9302194D0 (en) 1993-10-28
DE69318077D1 (de) 1998-05-28
HU219637B (hu) 2001-06-28
HUT68602A (en) 1995-06-28
IL106516A0 (en) 1993-11-15
RU2118959C1 (ru) 1998-09-20
NZ248285A (en) 1994-07-26
FI933391A7 (fi) 1994-02-01
BR9303235A (pt) 1994-03-01
NO932745D0 (no) 1993-07-30
EP0581552A2 (en) 1994-02-02
MX9304611A (es) 1994-02-28
PL172830B1 (pl) 1997-12-31
DE69318077T2 (de) 1998-10-29

Similar Documents

Publication Publication Date Title
NO303734B1 (no) Triazolyltiometyltiocefalosporin-hydroklorid, dets krystallinske hydrat samt farmasaytisk preparat inneholdende dette
AU616838B2 (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro- 2h-benzopyran or dihydrobenzodioxin)carboxamide derivatives
IL96550A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
AU2232288A (en) Novel substituted n-(1-alkyl-3-hydroxy-4-piperidinyl) benzamides
AU4236889A (en) Imidazoline derivative and preparation thereof
AU7436691A (en) Novel 2,9-disubstituted-4H-pyrido(1,2-a)pyrimidin-4-ones
AU3917189A (en) Antipsychotic 3-piperazinyl benzazole, benzisoxazole and benzisothiazole derivatives
FI933719A0 (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol